Elise Biopharma

Elise Biopharma is a South Korean biotechnology company focused on the discovery and development of novel small molecule therapeutics for oncology and inflammatory diseases. Founded in 2020 by Dr. Seong-Jin Kim, a pioneer in TGF-beta research, the company leverages deep expertise in signaling pathways to target the tumor microenvironment. Its lead program, EB-101, is a selective TGF-beta inhibitor aimed at overcoming resistance to immune checkpoint inhibitors in solid tumors. The company utilizes a proprietary drug discovery platform to identify high-potency candidates with optimized safety profiles. Elise Biopharma is currently advancing its pipeline through pre-clinical development with the goal of entering clinical trials.